Latest News
Novartis secures European approval for remibrutinib in chronic spontaneous urticaria
...
Evofem signs exclusive deal to expand SOLOSEC distribution in sub-Saharan Africa
27 April 2026 - Women's health company Evofem Biosciences Inc (OTCID: EVFM) disclosed on Monday that it has entered into an exclusive distribution agreement with pharmaceutical distributor Clovis Davis Pharmaceuticals, LLC to commercialise SOLOS...
GSK secures US and EU fast-track designations for efimosfermin in MASH
27 April 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) announced on Monday that it has received Breakthrough Therapy Designation from the US Food and Drug Administration, as well as Priority Medicines (PRIME) designation from the Eu...
Shield Therapeutics announces Phase II trial initiation of ACCRUFeR in Japan for PAH
27 April 2026 - Pharmaceutical company Shield Therapeutics plc (LSE: STX) announced on Monday that its partner MEDLEAP Pharma, a subsidiary of Vital KSK Holdings Inc, has enrolled the first patient in a Phase II clinical trial of ACCRUFeR (ferric mal...
Veradermics reports positive Phase 2/3 results for oral VDPHL01 in pattern hair loss treatment
27 April 2026 - Veradermics Inc (NYSE:MANE), a late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, on Monday announced positive topline results from its Phase 2/3 Study '302' evaluating ...